Home > News > Little Drug, Big Sales
August 13th, 2007
Little Drug, Big Sales
Abstract:
Huge increases in revenue usually drive stock prices upward, but Abraxis BioScience's (Nasdaq: ABBI) stock has fallen 15% from its high last week, despite releasing a stellar earnings report. It appears that investors -- myself included -- are having trouble determining the future value of the company after its breakup later this year.
For the quarter, revenue rose 51% year over year, to $242.5 milllion. Much of that increase was due to Abraxis' nanoparticle drug ABRAXANE, which saw a 117% increase in revenue, including deferred revenue of $9.1 million from a $200 million upfront payment from marketing partner AstraZeneca (NYSE: AZN). According to June's IntrinsQ data, ABRAXANE is now the leading taxane given to metastatic breast cancer patients, surpassing Bristol-Myers Squibb's (NYSE: BMY) Taxol and Sanofi-Aventis' (NYSE: SNY) Taxotere.
Source:
fool.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Simulating magnetization in a Heisenberg quantum spin chain April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||